DNA damage at the dawn of micro-RNA pathway impairment in pulmonary arterial hypertension by Francois Potus, Marie LeGuen, Steeve Provencher, Jolyane Meloche, Sebastien Bonnet
RNA & DISEASE 2015; 2: e810. doi: 10.14800/rd.810; © 2015 by François Potus, et al. 
http://www.smartscitech.com/index.php/rd 
Page 1 of 12 
DNA damage at the dawn of micro-RNA pathway impairment in 
pulmonary arterial hypertension 
François Potus*, Marie Le Guen*, Steeve Provencher , Jolyane Meloche, Sébastien Bonnet
Pulmonary Hypertension and Vascular Biology Research Group from the Quebec Heart and Lung Institute, Department of Medicine, 
Laval University, Quebec City, Quebec, G1V 4G5 Canada 
*The authors have equally contributed to this review
Correspondence: Jolyane Meloche or François Potus 
E-mail: Jolyane.Meloche@criucpq.ulaval.ca or Francois.Potus@criucpq.ulaval.ca
Received: April 27, 2015
Published: November 24, 2015
Over the last years, small non-coding microRNAs (miRNAs) have emerged as central actors of PAH etiology. 
Strong miRNA expression disorders occur in lungs as well as in right ventricle (RV) of PAH patients, which 
respectively lead to vascular remodeling of the distal pulmonary arteries and to RV failure. On the other hand, 
our understanding of PAH physiopathology has recently increased with the implication of DNA damage and 
DNA damage response (DDR) in this disease. Interestingly, DDR was described as a regulator of miRNA 
processing in both healthy and pathological conditions. In this review, we will first summarize miRNA 
expression impaired in lung and RV of PAH patients, then we will provide evidence that DDR could be at the 
origin of miRNA pathway defects observed in pulmonary hypertension. 
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Introduction 
Pulmonary arterial hypertension (PAH) is a lethal 
vasculopathy clinically defined by a mean pulmonary arterial 
pressure over 25 mmHg at rest. Histologically, PAH is 
characterized by vascular remodeling of the distal pulmonary 
arteries, which leads to decreased lung perfusion and 
sustained elevation of pulmonary vascular resistance [1]. In 
response to increased resistance, the right ventricle (RV) 
enters a compensatory state (hypertrophy) and ultimately 
becomes insufficient, which culminates to RV dilatation and 
failure [2]. Symptomatically, PAH patients display a variety 
of non-specific symptoms, including dyspnea, exercise 
intolerance and dizziness. As a result, there is an average 
delay of 2.8 years from symptom onset to diagnosis, during 
which time the patients’ physical condition deteriorates. 
Thus, the diagnosis often occurs when patients already 
experience advanced stages of pulmonary hypertension [3].  
Despite recent therapeutic advances, which led to 
improvement in quality of life and survival for a subset of 
patients, PAH remains a devastating disease with poor 
long-term survival (7-year survival rate of 49% post 
diagnosis) and unsatisfactory treatment progress [4,5]. To this 
day, most of the medication focuses on vasodilation of the 
pulmonary arteries, may it be prostanoids, endothelin 
receptor antagonists, phosphodiesterase 5 inhibitors, soluble 
guanylate cyclase stimulants or, in some rare cases, calcium 
channel blockers [6]. However, literature now widely 
describes PAH as complex impairments at the molecular 
level not only in the lung, but also in the RV and skeletal 
muscles of patients, all of which could explain the poor 
efficacy of treatments [7,8]. At the cellular level, PAH is 
associated with enhanced inflammation, proliferation and 
resistance to apoptosis of pulmonary artery smooth muscle 
cells (PASMCs) and endothelial cells (PAECs), as well as 
skeletal muscle and cardiomyocyte impairment, revealing 
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complex processes that remain far from being completely 
understood [7,9,10].  
Recently, microRNAs (miRNAs) have been extensively 
involved in both healthy and pathological vascular processes 
[11] such as wound healing [12], development of pulmonary 
vessels, tumor angiogenesis [13], as well as the 
proliferation/apoptosis imbalance observed in vascular 
remodeling diseases [14]. Over the past decade, an exponential 
number of articles demonstrated the crucial role of miRNAs 
in PAH [15]. MiRNA biogenesis is a multistep process. 
Briefly, primary miRNAs (pri-miRNA) are transcribed by 
the RNA polymerase II or III [16,17]. The pri-miRNAs are then 
recognized and cleaved by the microprocessor complex 
composed of the RNase III enzyme Drosha and the cofactor 
DiGeorge syndrome critical region 8 (DGCR8 also named 
Pasha), resulting in a 60-70 nucleotides hairpin-shaped 
structure: the precursors miRNAs (pre-miRNA) [17]. 
Pre-miRNAs are subsequently exported out of the nucleus by 
exportin-5 and, once they are in the cytoplasm, they can be 
cleaved by the endonuclease Dicer into microRNA duplexes. 
Binding of these duplexes to the Argonaute proteins Ago2 
allows the assembly of the RNA-induced silencing complex 
(RISC). Then, the association of mature miRNA to RISC 
leads to inhibition of translation or degradation of targeted 
messenger RNA (mRNA). It is now well established that 
miRNAs play a key role in each step of PAH etiology and 
progressiveness. Nevertheless, the origin of this disorder 
remains elusive. Interestingly, it was shown that miRNA 
expression could be regulated after DNA damage by DNA 
repair processes [18]. On the other hand, another level of 
complexity was recently added to PAH etiology with the 
identification of impairment in DNA repair mechanisms 
suggesting that the disorders implicated in this disease occur 
even at molecular scale [19,20]. 
In this review, we will firstly focus on the close link 
between disrupted miRNA expression and pathological 
processes in both lung and right ventricle in PAH patients 
and, secondly, based on recent studies, provide evidence that 
DNA damage could be at the origin of disrupted miRNA 
pathways observed in PAH. 
Vascular remodeling in pulmonary arterial hypertension 
It is now widely established that PAH is associated with 1) 
imbalance between pulmonary artery vasoconstriction and 
vasodilatation, as well as 2) vascular remodeling of the small 
pulmonary arteries associated with increased proliferation 
and suppressed apoptosis of PASMCs and PAECs [21,22], 
which ultimately leads to obstruction of the arteries. In the 
past 5 years, miRNAs were systematically implicated in the 
establishment and the progression of the vascular 
transformations observed in this disease. 
Misexpression of miRNAs in PAH lung 
The imbalance between vasodilation and vasoconstriction 
observed in pulmonary arteries of PAH patients was strongly 
associated with impaired miRNA expression (Figure 1). For 
example, miR-143/145 and miR-21 are overexpressed in 
pulmonary arteries of PAH patients. They modulate vascular 
smooth muscle cells actin cytoskeleton and thus control their 
contractility, which is essential for regulating blood pressure 
in resistance vessels. Furthermore, deregulation of miR-155 
expression was also found in PAH and associated with 
Figure 1. A schematic representation of micro-RNA and some of their targets implicated in 
vasoconstriction/vasodilation and vascular remodeling of the distal pulmonary arteries in PAH. AT1R: 
Angiotensin Type 1 Receptor; BCL2: B Cell Lymphoma 2; KLF4: Kruppel-like factor 4; KLF5: Kruppel-like factor 5; 
BMPR2: Bone morphogenetic receptor type II, STAT3; Signal transducer and activator of transcription 3. 
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human Angiotensin II Type 1 Receptor expression [23], which 
is the most important effector of Angiotensin II-mediated 
vasoconstriction [24].  
Interestingly, miRNA expression impairment was also 
associated with the proliferation/apoptosis imbalance, which 
plays a crucial role in pathological muscularization of the 
distal segment of the pulmonary arterial tree in PAH (Figure 
1). Since miRNAs have multiple targets, one deregulated 
expression might have many downstream effects, which 
amplifies the impact of impairment in miRNA expression. 
For example, many tumor suppressor genes, such as PTEN 
and Bcl-2 [25-27], as well as KLF4 and Myocardin [28-33] are 
targeted by miRNAs, in this case miR-21 and miR-145 
respectively. This inhibition drives proliferation and 
suppresses apoptosis within PASMCs. Among others, Caruso 
et al. demonstrated that miR-145 downregulation decreased 
vascular remodeling in chronic hypoxia-induced PAH mice 
model and that miR-145 modulation in human PASMCs 
controlled proliferation levels [28]. Furthermore, blocking 
miR-21 also attenuated remodeling of the distal pulmonary 
arteries in hypoxia-exposed mice and regulated PASMCs 
proliferation in vitro [25]. Using the same PAH model, 
increasing miR-210 expression exhibited an anti-apoptotic 
effect in PASMCs by targeting the transcription factor E2F3 
in lungs of PAH mice [34]. On the other hand, it was recently 
shown that inhibition of miR-17 increased p-21 expression 
and reduced lung vascular remodeling in chronic hypoxia 
mouse model as well as in the monocrotaline-induced PAH 
rat model [35]. Note that miR-17 is part of the miR17/92 
cluster, which carries out pleiotropic effects during both 
healthy development and malignant transformation, as it 
triggers proliferation, blocks differentiation, and maintains 
cell survival [36]. Interestingly miR-17/92 expression 
correlates with bone morphogenetic protein receptor II 
(BMPR2) protein expression in a STAT3-dependant manner 
in human PAEC [37], a pathway which was recently shown to 
be modulated by DNA damage as discussed below. 
Furthermore, STAT3 is strongly implicated in PAH 
pathogenesis notably by regulating NFAT expression, which 
leads to increased proliferation and suppressed apoptosis of 
PAH-PASMCs. Our group showed that restoring miR-204 
levels in PAH experimental models was able to decrease 
STAT3 activation, via an alteration in the Shp2/Src pathway, 
leading to reestablishment of normal proliferation and 
apoptosis rates and thus reopening of the vascular lumen of 
distal pulmonary arteries in these PAH rodent models [38]. 
Interestingly, a tight relationship between STAT3 and 
Notch-1, which is also highly expressed in both the mouse 
model of hypoxia-induced PAH and the rat model of 
monocrotaline-induced PAH, was recently described and 
associated with pro-proliferative phenotype of human 
PASMCs [39,40]. MiR-34, which is decreased in PAH [41], 
induces apoptosis by repressing Notch1 expression, also 
known to activate the anti-apoptotic proteins Survivin and 
Bcl-2 [42,43]. It is well established that alteration of Bcl-2 
expression plays a key role in the PAH pulmonary artery 
remodeling and is closely linked to impairment in miRNA 
expression [44]. Indeed, this pro-apoptotic protein is targeted 
by multiple miRNA such as miR-21 and particularly by 
miR-155 [45], which decreases apoptosis by inhibiting 
FOXO3a, a protein associated with extensive vascular 
growth [46-50]. Interestingly, increased miR-138 expression in 
rat PASMCs was also associated with reduced apoptosis 
through disruption of Bcl-2 signaling and Akt 
phosphorylation, as well as by decreasing caspase-3 and -9 
activities; thus contributing to vascular remodeling of distal 
pulmonary arteries [51,52][52]. 
As discussed above, literature widely describes defects in 
miRNA expression as a crucial actor of lung vasculature 
impairment observed in PAH by targeting 
vasoconstriction/vasodilation and vascular remodeling 
processes. Note this review does not aim to be exhaustive. 
Nevertheless, the implication of miRNA lung 
physiopathology of PAH patients was summarized and, 
recently, impairment of miRNA expression was also found to 
play a critical role in the heart of PAH patients. 
Right ventricle in pulmonary arterial hypertension 
Right ventricular failure is the main cause of death in PAH 
and its status appears as the most important indicator of both 
morbidity and mortality [53]. Interestingly, it now clearly 
appears that RV failure observed in PAH is not only a 
consequence of increased afterload [54], but is associated with 
strong impairment of RV function itself with a specific 
molecular signature [55]. The specific mechanisms underlying 
RV impairment in PAH remain unclear. Nonetheless, the 
literature widely demonstrated the strong implication of 
miRNAs in RV failure [56]. 
MicroRNA impairment in right ventricle 
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During the transition from a healthy to a decompensated 
RV, the expression of more than 100 miRNAs is altered 
suggesting a strong impairment of miRNAs pathways in the 
physiopathology of RV failure. Note that miRNAs defects 
occur in endothelial cells [9], as well as cardiomyocytes, 
explaining the large physiological impairment on 
angiogenesis [13], fibrosis [57], metabolism [58] and 
hypertrophy [59] involved in the pathogenesis and progression 
of RV failure (Figure 2). Micro-array performed on failed 
RV of chronic hypoxia and Sugen-induced PAH rat models 
displayed downregulation of 59 miRNAs and increased 
expression of 7 miRNAs compared to control rats [60]. On the 
other hand, only 9 miRNAs were found increased and 19 
decreased in decompensated RV of late pulmonary artery 
banding mice model compared to compensated RV [61]. 
Interestingly, only 5 miRNAs were decreased in 
decompensated RV of both mice (late pulmonary artery 
banding) and rats (hypoxia and sugen model) suggesting that, 
despite differences in species and models of disease, 
miR-144, miR-185, miR-30b* miR-345* and miR-451 play 
key roles in RV failure in pulmonary hypertension. 
Curiously, these miRNAs were poorly studied in the 
failing heart and even less in pulmonary hypertension. 
Nevertheless, Song et al. recently showed that, by targeting 
TSC1, miR-451 was implicated in the regulation of cardiac 
hypertrophy and autophagy [62], which was recently described 
as an important actor in PAH-induced RV hypertrophy and 
diastolic heart failure [63]. MiR-451 expression is also altered 
in human heart diseases [64,65], confirming that miRNAs play 
a key role in cardiac function. Interestingly, miR-451 and 
miR-144 are frequently associated in the miR144/451 cluster 
and play an important role in hypertrophic 
ischemia/reperfusion process. Indeed, it was shown that 
miR-144/451 protects against ischemia/reperfusion-induced 
cardiomyocyte death through CUGBP2-COX-2 pathway [66]. 
Figure 2. A schematic representation of micro-RNAs implicated in different 
abnormalities observed in the right ventricle (RV) in PAH patients, such as 
maladaptive hypoxia response, impaired angiogenesis, RV hypertrophy, 
cardiomyocyte death, mitochondrial dysfunction, autophagy and fibrosis. 
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Moreover, loss of the miR-144/451 cluster leads to excessive 
production of ROS via activation of Rac-1-mediated 
oxidative stress signaling, thus resulting in myocardial 
apoptosis and therefore in impaired cardiac function [67]. By 
targeting cyclophilin D, miR-30b also improves 
ischemia/reperfusion injury and decrease cells necrosis and 
could prevent heart failure [68]. Furthermore, miR-30b 
directly inhibits PDGFR-β expression in fibroblasts, which 
plays a crucial role in promoting fibrosis suggesting that 
decreased miR-30b expression could be linked to increased 
myocardial fibrosis [69]. This miRNA also plays a role in 
aortic stenosis calcification by directly targeting the 
transcription factor Runx2 [70], which has recently been 
suggested to be implicated in PAH [9,71]. Moreover, members 
of the miR-30 family were abundantly expressed in the heart 
and involved in mitochondrial dynamics. Among other 
functions, they control mitochondrial fission and apoptosis 
through p53 and DRP-1 axis [72] (note that both DRP-1 [73] 
and p53 expression are strongly affected in PAH [74]). 
Interestingly miR-30b was found as a positive regulator of 
angiogenesis through DLL4 (Delta like ligand 4) [75] 
suggesting that decreased miR-30b expression in the RV 
could lead to the angiogenic impairment observed in PAH. 
MiR-30b seems to be linked to most of the pathological 
processes implicated in PAH-induced RV failure and is also 
implicated, in association with miR-185, in the hypoxia 
response by directly targeting HIF-1α, HIF-2α and 
controlling consequent HIF-dependent adaptive response 
[76,77]. On the other hand, the role for miR-345 remains 
elusive and its function understudied. It was shown that 
miR-345 could prevent apoptosis by targeting 
Bcl-2-associated athanogene 3 (BAG-3) in cancer cells [78]. 
MiR-345 was also strongly decreased in cardiomyopathic 
hypertrophic heart of diabetic mice associated with increased 
inflammation [79], but its specific role in PAH RV 
pathogenesis remains unknown. Finally, decreased miR-144, 
miR-185 miR-30b* miR-345* and miR-451 expression could 
explain the maladaptive hypoxia response, impaired 
angiogenesis, mitochondrial metabolism dysfunction, 
cardiomyocyte death, autophagy and fibrosis observed in 
PAH RV failure. Nevertheless, despite their crucial role in 
PAH, the mechanisms by which miRNA pathways 
impairment occurs remain unknown. 
Regulation of miRNA expression by DNA damage 
DNA damage was shown to regulate miRNA expression 
in normal human fibroblasts exposed to different genotoxic 
stresses [80] and to induce upregulation of about one-fourth of 
miRNAs in mouse embryonic fibroblasts [81]. The expression 
of most of these miRNAs apparently depend on the 
ataxia-telangiectasia mutated kinase (ATM), which is, with 
the other phosphatidylinositol 3-kinase-related kinases, 
ataxia telangiectasia Rad3 kinase (ATR) and 
DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs), one of the major kinase recruited by DNA 
damage to initiate DNA damage response [81]. In this study, 
the authors shed light on the implication of the KH-type 
splicing regulatory protein (KSRP) as a link between ATM 
and miRNAs expression in response to DNA damage. KSRP, 
which appears to be part of both Drosha and Dicer 
complexes [82], promotes processing of a subset of miRNAs 
recruited by DNA damage in an ATM-dependent manner [81]. 
The implication of KSRP highlighted the fact that DNA 
damage response pathways can act at a post-transcriptional 
level to control miRNA expression. However, not all the 
miRNAs upregulated in response to DNA damage depend on 
KSRP activity suggesting the existence of other mechanisms. 
ATM and ATR are known to activate a range of downstream 
effectors such as p53 [83,84] and MDM2 (Mouse double 
minute 2 homolog) [85]. P53 has also been shown to act on 
miRNA expression at a post-transcriptional level [86]. Indeed, 
p53 interacts with the Drosha complex through an 
association with one of its components, the Dead-box RNA 
helicase 68 (also called DDX5). This interaction between 
p53 and the Drosha complex facilitates the pri-miRNA to 
pre-miRNA process [87]. Moreover, besides its effects on 
miRNA maturation, p53 can also directly increase miRNA 
expression as a transcription factor [88]. 
DNA damage in PAH 
DNA damage is a normal and frequent phenomenon, as 
cells are constantly exposed to genotoxic agents [89,90][90] with 
an estimation of up to 105 spontaneous DNA damages per 
day in each human cell [91]. In response to these "attacks", 
healthy cells adapt to this deleterious condition by 
developing DNA damage response (DDR) pathways that first 
sense and signal DNA damage and then aim to restore DNA 
integrity (DNA repair) and maintain cell survival. However, 
if repair capacities are exceeded or if the DDR pathways are 
blocked, cell senescence or apoptosis will be triggered [92], 
which prevents cancer development or pathologic 
proliferation of cells [91]. Indeed, defects in DDR could 
contribute to the establishment of various pathologic 
affections from cancer to cardiovascular diseases. 
PAH is strongly associated with chronic hypoxia and 
systemic inflammation [93-95], both being extensively studied 
as potent modulators of transcription factors’ expression in 
PAH pathophysiology. On the other hand, it is now well 
established that chronic hypoxia and inflammation were 
associated to a stressful environment and that cells exposed 
to these harmful conditions will have increased DNA damage 
and activation of their DDR machinery. Furthermore, 
Meloche and colleagues recently displayed that DNA 
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damage repair pathways were strongly implicated in lung 
pathophysiological phenotype of PAH patients [20]. 
Moreover, there is an increase in harmful DNA damage in 
the failing heart, as well as in other cardiovascular diseases 
[96], and particularly implicated in myocyte dysfunction [97]. 
More recently, extensive DNA damage was described in the 
RV of PAH rat models [98]. Note that as discussed above, 
DNA damage and DDR were shown closely linked to 
miRNA expression and regulation [18,99]. In the second part of 
this review, we will focus on the regulation of miRNAs 
expression by the DNA damage pathway in PAH. 
DDR in PAH 
Deregulation of DDR is a common feature of diseases 
such as cancer, neurodegenerative disorders, immunological 
defects and also aging [91,92,100-103]. DNA damage in lung and 
more precisely in PASMCs was recently demonstrated by 
our group as a hallmark of PAH pathophysiology [20]. We 
also demonstrated that, in PAH, the greater the DNA 
damage, the higher the poly(ADP-ribose) polymerase-1 
(PARP-1) expression and activity were in human PASMCs. 
PARP-1 is a key player in the DNA repair machinery and we 
confirmed that inhibition of PARP-1 expression by siRNA or 
by a clinically available inhibitor, ABT-888, led to increased 
DNA damage, due to lack of repair. Moreover, inhibition of 
the PARP-1-mediated DNA damage response in human 
PAH-PASMCs, as well as in two animal models of PAH, 
restored the proliferation/apoptosis balance and reversed 
subsequent vascular remodeling. Thus, this work suggested 
that DDR is deregulated in PAH and favors vascular 
remodeling. Furthermore, PARP-1 inhibition was associated 
with restoration of miR-204 levels and decrease of its 
downstream targets HIF-1α and NFAT [20], which could 
explain at least in part the restoration of normal apoptosis 
and proliferation balance. This work highlighted the 
necessity of studying DDR regulation of miRNAs in the 
context of PAH. 
Altered miRNA pathways by deregulated DDR in PAH 
Expression of all the miRNAs described above; miR-185 
and miR-345 [104], miR-144, miR-30b, miR-451, miR-21, 
miR-143/145 [105], miR-155 [106], miR-17/92 [104] and 
Figure 3. Schematic representation of interaction between disrupted miRNAs 
and DNA damage in the physiopathology of PAH. Black arrows represent 
activation and red arrows represent inhibition. HDM2 and 4: Human homolog of 
murine double minute 2 and 4. 
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miR-204 [20] were found affected by DNA damage and /or 
DDR in human disorder such as cancer and cardiovascular 
disease (Figure 3). 
More precisely, the tumor protein p53 was firstly 
described as a central actor in DDR [102] and miRNA 
regulation [87] and, more recently, associated with PAH 
physiopathology. Indeed, impaired expression of p53 has 
been related to increased expression of the onco-miRNA 
cluster miR-17/92 [107], as well as decreased expression of 
miR-34 [74], miR-210 [108] and miR-143/145 [87], which are all 
involved in the regulation of proliferation and apoptosis 
balance.  
Note that p53 is regulated by the oncogenic transcription 
factor Myc [109] which was also described as 1) an important 
regulator of DDR [110] and 2) strongly implicated in miRNA 
function [111]. Indeed, in a healthy situation, this factor is 
repressed in a p53-dependent manner [112], while in 
pathologic condition such as PAH, Myc is increased [113] and 
induces DNA damage, notably through ROS induction [114]. 
Myc was notably shown to increase the expression of the 
oncomiRs miR-185 [115] and miR-30b [116], as well as the 
miR-17/92 and miR144/451 clusters [117,118] by directly 
binding to their promoter region [119]. 
Interestingly, other factors related to DDR can modulate 
miRNA expression. For instance, Chaudhry et al. showed 
that miR-155 upregulation only occurs in DNA-PKcs kinase 
proficient cells [120]. Moreover, miR-155 overexpression 
seems to be linked with decreased DNA repair mechanisms 
leading to higher mutation rates in several cancers [121]. Since 
PAH and cancer share many hallmarks, it seems very 
interesting to benefit from cancer research done on the link 
between DDR and miRNAs, as it has been more widely done 
than in PAH. 
Heterozygous mutation of the BMPR2 gene is the most 
important mutation observed in PAH. The encoded protein 
plays a critical role in PAH lung physiopathology and studies 
showed strong implication of miRNAs such as miR17-92 
cluster in this molecular pathway [37]. On the other hand, it 
was recently shown that loss of BMPR2 is associated with 
abnormal DNA repair in PAH [19] confirming the tight link 
between DNA damage and miRNAs in PAH. Thus, more 
studies are needed to fully understand the role for DDR and 
miRNAs in known pathways implicated in PAH 
pathogenesis and these further investigations will probably 
reveal more downstream effects of these interactions. 
Altered miRNA pathways could also alter DDR 
It was shown that DNA damage and DDR mechanisms 
can modify miRNA expression (Figure 3). Conversely, 
evidences showed that miRNAs involved in PAH could also 
alter DDR mechanisms. For example, Huang and colleagues 
have demonstrated that miR-210 impairs DNA damage 
response, more precisely through the inhibition of RAD52 
protein, a key component of DDR mechanism [122] and the 
mediator of DNA damage induced apoptosis E2F3 [123]. 
A feedback loop between DDR and miRNA expression 
was already established in the literature in physiological as 
well as pathological condition [18,124,125]. Interestingly Zhang 
et al. described a feedback loop between 
p53/MDM2/miR143/145 [105]. Indeed, as described above, 
DNA damage induces p53 expression, which leads to 
miR-143/145 expression and, on the other hand, 
miR-143/145 can negatively modulate MDM2 expression, 
which inhibits the transcriptional activation function of p53 
[126]. In the same way, p53/miR-34 [127] positive feedback 
loop through HDM4 was also described in cancer. Note that 
p53 was also shown as a direct target of miRNA implicated 
in distinct physiological process: miR-138 in controlling 
stem cells fate [128] and miR-30b in the control of 
mitochondrial fission process [129]. 
As discussed above, miR-30b expression is controlled by 
Myc, a transcription factor that was also described as tightly 
linked to miRNA expression. Indeed, Liao and colleagues 
[115] identified auto-regulatory feedback mechanisms between 
miR-185 and Myc and confirmed that decrease of miR-185 
and increase of Myc [130] observed in PAH right ventricle 
were closely linked. As observed for p53, Myc is also 
targeted by other miRNAs implicated in PAH 
pathophysiology such as miR143/145 [131], miR-34 [132], 
miR-451 [133], and indirectly by miR-210 through MNT [134] 
as described in cancer, resulting in impairment of Myc 
function.  
This tight and reciprocal regulation of miRNA by DDR 
mechanisms was already well described in cancer, which 
highlights the complexity of these relationships in 
pathological processes. In the present review, we focused and 
displayed that specific and mutual regulations also occur 
with DDR actors and impaired miRNA expression involved 
in PAH. Crosstalk between miRNAs and DDR mechanisms 
is one step ahead in the understanding of PAH etiology, but 
still remains far from being fully understood. 
Conclusion 
In the past decade, impairment of miRNA expression was 
widely recognized as a central actor in PAH etiology. As 
described above, miRNA defects occur in each cellular type 
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from lung to right ventricle suggesting a real “miRNA 
pathways” impairment in PAH. Nonetheless, the mechanisms 
implicated in miRNA impairment remained elusive. On the 
other hand, DNA damage response was recently implicated 
in PAH etiology and in heart failure as well as in regulation 
of miRNA expression. In this review, we provide evidence 
that DDR could act as a trigger to extensive miRNA 
pathways impairment observed in both lung and RV of PAH 
patients. Indeed, most of miRNA implicated in PAH are 
regulated by DDR, suggesting that targeting DDR could 
affect all the miRNA pathway expression impaired in PAH 
and thus correct cellular and physiological defects observed 
in PAH.  
Targeting DDR for therapies is currently in clinical trials 
for cancer with promising results. Therefore, there is a hope 
for DDR based therapies in other diseases, such as PAH, 
which seems to be the case with in vivo studies of PARP-1 
inhibitors [20]. Therefore, additionally to shedding the light 
pathological mechanisms of PAH, research in the field of 
DDR and miRNA opens the door to new promising targets 
for this devastating disease. 
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